MALLINCKRODT PLC

Company Overview

Mallinckrodt is an international enterprise comprising numerous wholly-owned subsidiaries engaged in the development, manufacture, marketing and distribution of specialized pharmaceutical products and therapies. Within the Specialty Brands reportable segment, the company concentrates on autoimmune and rare diseases, with expertise in neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Additionally, the company’s focus extends to immunotherapy and therapies critical for neonatal respiratory care, as well as analgesics and GI products. The Specialty Generics reportable segment encompasses specialty generic drugs and APIs.

In September 2023, Mallinckrodt obtained a label update from the U.S. FDA for StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat), leading to a reduction in xenotransplantation requirements.

Financial Highlights (FY 2023)

Company's Business Segments

• Specialty Brands : Branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology rheumatology hepatology nephrology pulmonology ophthalmology and oncology, Immunotherapy and neonatal respiratory critical care therapies, Gastrointestinal products
• Specialty Generics : Hydrocodone-containing tablets, Oxycodone-containing tablets, Several other controlled substances indicated for the treatment of pain, Medicines used to treat attention-deficit/hyperactivity disorder ("ADHD"), Addiction treatment medications